WebApr 10, 2024 · PRINCETON, N.J., April 10, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release … WebAug 5, 2024 · Total revenue for the second quarter of 2024 was $70.1 million, representing year-over-year growth of 15%. The revenue growth was driven by both technology-driven services and software licenses and subscriptions. Total cost of revenue for the second quarter of 2024 was $27.5 million, an increase from $20.6 million in the second quarter of …
Certara Announces Proposed Public Offering of Common Stock
WebSep 1, 2024 · September 1, 2024. PRINCETON, N.J.—September 1, 2024 . Certara, the global leader in biosimulation, today announced changes to its board of directors, which took effect August 26, 2024. After successfully transitioning the leadership of Certara to Chief Executive Officer William Feehery, Edmundo Muniz has decided to step down from the … WebApr 5, 2024 · d3 Medicine and the Defence Science and Technology (DST) Group will review the country’s medical countermeasures product R&D skills and infrastructure . PRINCETON, NJ – Apr. 5. 2024 – Certara ®, the leading provider of decision support technology and consulting services for optimizing drug development and improving … clifford leafs
Certara Reports Fourth Quarter and Full Year 2024 …
WebApr 10, 2024 · PRINCETON, N.J., April 10, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of ... WebSep 3, 2024 · September 3, 2024. PRINCETON, N.J.—September 3, 2024. Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Certara is offering … WebMay 17, 2024 · PRINCETON, N.J.—May 17, 2024. Certara, Inc, (Nasdaq: CERT), the global leader in biosimulation, announced the appointments of four executives to its growing model-informed drug development team: Dr. Matt Zierhut as Vice President, Model-Based Meta-Analysis, Dr. James Dunyak as Senior Director, Biostatistics and Data … clifford l boggs of irondale oh